Evidence map›Paper›PMID 31636067›Full record

ArticleAntimicrobial agents and chemotherapy2019

DAV131A Protects Hamsters from Lethal

Nathalie Saint-Lu, Charles Burdet, Frédérique Sablier-Gallis, Tanguy Corbel, Agathe Nevière, Sakina Sayah-Jeanne, Mark Pulse, William Weiss, Stéphanie Ferreira, Antoine Andremont and 2 more

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Nathalie Saint-LuDa Volterra, Paris, France.
Charles BurdetUniversité de Paris, IAME, INSERM, Paris, France.
Frédérique Sablier-GallisDa Volterra, Paris, France.
Tanguy CorbelDa Volterra, Paris, France.
Agathe NevièreDa Volterra, Paris, France.
Sakina Sayah-JeanneDa Volterra, Paris, France.
Mark PulseUNT Health Science Center, Fort Worth, Texas, USA.
William WeissUNT Health Science Center, Fort Worth, Texas, USA.
Stéphanie FerreiraGenoScreen, Lille, France.
Antoine AndremontUniversité de Paris, IAME, INSERM, Paris, France.
France MentréUniversité de Paris, IAME, INSERM, Paris, France.
Jean de GunzburgDa Volterra, Paris, France gunzburg@davolterra.com.ORCID 0000-0001-8049-9283
Da Volterra (France) · FRInserm · FRUniversity of North Texas · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fluoroquinolone treatments induce dysbiosis of the intestinal microbiota, resulting in loss of resistance to colonization by exogenous bacteria such as

Indexed as

Clostridioides difficileAdministration, OralAdsorptionAnimalsAnti-Bacterial AgentsCharcoalCiprofloxacinClostridium InfectionsDisease Models, AnimalDysbiosisFluoroquinolonesGastrointestinal MicrobiomeLevofloxacinMaleMesocricetusAnti-Bacterial AgentsCharcoalCiprofloxacinFluoroquinolonesLevofloxacinantibioticsClostridioides difficile infectiondysbiosisfluoroquinoloneshamster animal modelprevention

Identifiers

PMID31636067
PMCPMC7187614
OpenAlexW2980998034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.